Description
TNG260 is an experimental oral medication currently being studied in clinical trials for certain types of solid tumors, including colorectal cancer. It is being investigated in combination with pembrolizumab (an immunotherapy drug) for patients whose tumors have a specific genetic change called an STK11 mutation. This trial is in Phase 1, which means it is primarily focused on determining the right dose and assessing the safety and side effects of the combination therapy. The goal is also to see if the combination shows early signs of effectiveness (antineoplastic activity) in these patients. TNG260 is being developed by Tango Therapeutics, Inc.
Mechanism of Action
TNG260 is an oral medication designed to target specific proteins involved in tumor growth and survival. The specific molecular target is being characterized in clinical trials. It is thought to work by interfering with pathways that cancer cells rely on. In the current trial, it is being used in combination with pembrolizumab, which is an immunotherapy drug that helps the body's immune system recognize and attack cancer cells. The combination aims to target the tumor through multiple mechanisms.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.